{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:39:56Z","timestamp":1793173196147,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Vaccines Division"},{"name":"GlaxoSmithKline Biologicals SA"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.clim.2019.108275","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T12:22:11Z","timestamp":1571919731000},"page":"108275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine"],"prefix":"10.1016","volume":"209","author":[{"given":"Antonio","family":"Gonzalez-Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Oostendorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Koernicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Fadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"D'Oro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherryl","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek T.","family":"O\u2019Hagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Del Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oretta","family":"Finco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duccio","family":"Medini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 3","key":"10.1016\/j.clim.2019.108275_bb0005","doi-asserted-by":"crossref","first-page":"C25","DOI":"10.1016\/j.vaccine.2010.07.021","article-title":"Unmet needs in modern vaccinology: adjuvants to improve the immune response","volume":"28","author":"Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.clim.2019.108275_bb0010","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1016\/j.vaccine.2016.06.080","article-title":"Evaluation of novel synthetic TLR7\/8 agonists as vaccine adjuvants","volume":"34","author":"Smith","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.clim.2019.108275_bb0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3389\/fimmu.2014.00255","article-title":"Dendritic cell-targeted vaccines","volume":"5","author":"Cohn","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2019.108275_bb0020","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.immuni.2011.05.006","article-title":"Toll-like receptors and their crosstalk with other innate receptors in infection and immunity","volume":"34","author":"Kawai","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2019.108275_bb0025","doi-asserted-by":"crossref","first-page":"263ra160","DOI":"10.1126\/scitranslmed.3009980","article-title":"Rational design of small molecules as vaccine adjuvants","volume":"6","author":"Wu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.clim.2019.108275_bb0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4049\/immunohorizons.1700063","article-title":"Recent advances in the discovery and delivery of TLR7\/8 agonists as vaccine adjuvants","volume":"2","author":"Dowling","year":"2018","journal-title":"ImmunoHorizons"},{"key":"10.1016\/j.clim.2019.108275_bb0035","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjd.17124","article-title":"Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo-controlled, double-blind clinical trial","volume":"180","author":"Stockfleth","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2019.108275_bb0040","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40261-018-0681-x","article-title":"A review on imiquimod therapy and discussion on optimal management of basal cell carcinomas","volume":"38","author":"Kamath","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.clim.2019.108275_bb0045","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(15)00354-0","article-title":"Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b\/3 trial","volume":"16","author":"Hung","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.clim.2019.108275_bb0050","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1111\/j.1365-2230.2008.03181.x","article-title":"Pemphigus-like lesions induced by imiquimod","volume":"34","author":"Bauza","year":"2009","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.clim.2019.108275_bb0055","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1016\/j.jaad.2004.10.858","article-title":"Topical application of imiquimod and associated fever in children","volume":"52","author":"Campanelli","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clim.2019.108275_bb0060","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1517\/13543784.17.7.1051","article-title":"Clinical investigations of Toll-like receptor agonists","volume":"17","author":"Meyer","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.clim.2019.108275_bb0065","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1136\/sextrans-2011-050025","article-title":"Local and systemic adverse effects to topical imiquimod due to systemic immune stimulation","volume":"87","author":"Kumar","year":"2011","journal-title":"Sex. Transm. Infect."},{"key":"10.1016\/j.clim.2019.108275_bb0070","article-title":"Systemic adverse events in imiquimod use for cervical intraepithelial neoplasia - a case series","volume":"21","author":"Wouters","year":"2019","journal-title":"Case Rep. Womens Health"},{"key":"10.1016\/j.clim.2019.108275_bb0075","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.biomaterials.2018.02.034","article-title":"Polymeric nanoparticles encapsulating novel TLR7\/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy","volume":"164","author":"Kim","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.clim.2019.108275_bb0080","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126047","article-title":"Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques","volume":"4","author":"Petitdemange","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.clim.2019.108275_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2018.10.002","article-title":"Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01","volume":"291","author":"Wilkinson","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.clim.2019.108275_bb0090","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.91020","article-title":"TLR7\/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth","volume":"2","author":"Dowling","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.clim.2019.108275_bb0095","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2017.06.005","article-title":"Old and new adjuvants","volume":"47","author":"McKee","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.clim.2019.108275_bb0100","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1073\/pnas.1424924112","article-title":"Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus","volume":"112","author":"Bagnoli","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2019.108275_bb0105","doi-asserted-by":"crossref","DOI":"10.1038\/srep29063","article-title":"Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines","volume":"6","author":"Buonsanti","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clim.2019.108275_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147767","article-title":"One dose of Staphylococcus aureus 4C-staph vaccine formulated with a novel TLR7-dependent adjuvant rapidly protects mice through antibodies, effector CD4+ T cells, and IL-17A","volume":"11","author":"Mancini","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2019.108275_bb0115","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3389\/fimmu.2018.00641","article-title":"Alum\/toll-like receptor 7 adjuvant enhances the expansion of memory B cell compartment within the draining lymph node","volume":"9","author":"Vo","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2019.108275_bb0120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1517\/14712598.2.1.87","article-title":"Meningococcal serogroup C conjugate vaccine","volume":"2","author":"Lakshman","year":"2002","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.clim.2019.108275_bb0125","author":"Food and Drug Administration"},{"key":"10.1016\/j.clim.2019.108275_bb0130","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.xphs.2018.01.024","article-title":"The preparation and physicochemical characterization of aluminum hydroxide\/TLR7a, a novel vaccine adjuvant comprising a small molecule adsorbed to aluminum hydroxide","volume":"107","author":"Malyala","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.clim.2019.108275_bb0135","author":"European Medicines Agency"},{"key":"10.1016\/j.clim.2019.108275_bb0140","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection--serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.clim.2019.108275_bb0145","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/jcm.32.6.1475-1482.1994","article-title":"Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay","volume":"32","author":"Gheesling","year":"1994","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.clim.2019.108275_bb0150","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/bloodadvances.2017011411","article-title":"Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs","volume":"1","author":"Francica","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.clim.2019.108275_bb0155","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/cid\/cir198","article-title":"Kinetics of immune responses to nasal challenge with meningococcal polysaccharide one year after serogroup-C glycoconjugate vaccination","volume":"52","author":"Wing","year":"2011","journal-title":"Clin. Infect. Dis."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661619300737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661619300737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:58:28Z","timestamp":1761494308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661619300737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":31,"alternative-id":["S1521661619300737"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2019.108275","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2019.108275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108275"}}